NCT05242718 is a NA clinical trial of N-Acetyl-L-cysteine (NAC) in Immunity Disorders, sponsored by Immunoflex Therapeutics Inc..

Who is sponsoring NCT05242718?

NCT05242718 is sponsored by Immunoflex Therapeutics Inc..

What drugs are being tested in NCT05242718?

Interventions in NCT05242718: N-Acetyl-L-cysteine (NAC), Echinacea purpurea, Curcumin, Palmitoylethanolamide.

What condition does NCT05242718 study?

NCT05242718 studies Immunity Disorders.

Is NCT05242718 still recruiting?

NCT05242718 is currently completed. Last updated 16 February 2022.

Last reviewed 2022-02-16 · How we verify

NCT05242718

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Immune Diversity Response to Oral Dosing of Nutritional Health Products in Healthy Participants

Completed NA Last updated 16 February 2022

What this trial tests

NA trial testing N-Acetyl-L-cysteine (NAC) in Immunity Disorders in 32 participants. Completed in 20 May 2021.

Timeline

10 January 2021

Primary endpoint
1 May 2021

20 May 2021

Quick facts

Lead sponsor	Immunoflex Therapeutics Inc.
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	32
Start date	10 January 2021
Primary completion	1 May 2021
Estimated completion	20 May 2021
Sites	1 location across Canada

Drugs / interventions tested

N-Acetyl-L-cysteine (NAC) — full drug profile →
Echinacea purpurea — full drug profile →
Curcumin (CURCUMIN) — full drug profile →
Palmitoylethanolamide — full drug profile →

Conditions studied

Immunity Disorders — all drugs for Immunity Disorders →

Sponsor

Immunoflex Therapeutics Inc.

Who can join

Adults 60 to 70, any sex, with Immunity Disorders. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A Phase IV, open-label, adaptive, 4-arm, multi-dose, single-centre, exploratory trial to assess the immune diversity response to oral administration of licensed Natural Health Products, in healthy adults, 60-70 years of age.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05242718 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Immunoflex Therapeutics Inc.
Last refreshed: 16 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05242718.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing